GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » LTR Pharma Ltd (ASX:LTP) » Definitions » Accumulated other comprehensive income (loss)

LTR Pharma (ASX:LTP) Accumulated other comprehensive income (loss) : A$0.58 Mil (As of Jun. 2023)


View and export this data going back to 2023. Start your Free Trial

What is LTR Pharma Accumulated other comprehensive income (loss)?

Accumulated other comprehensive income (loss) is the aggregate amount of gains or losses that are not part of retained earnings. LTR Pharma's Accumulated other comprehensive income (loss) for the quarter that ended in Jun. 2023 was A$0.58 Mil.

LTR Pharma's quarterly Accumulated other comprehensive income (loss) increased from Jun. 2021 (A$0.00 Mil) to Jun. 2022 (A$0.05 Mil) and increased from Jun. 2022 (A$0.05 Mil) to Jun. 2023 (A$0.58 Mil).

LTR Pharma's annual Accumulated other comprehensive income (loss) increased from Jun. 2021 (A$0.00 Mil) to Jun. 2022 (A$0.05 Mil) and increased from Jun. 2022 (A$0.05 Mil) to Jun. 2023 (A$0.58 Mil).

LTR Pharma Accumulated other comprehensive income (loss) Historical Data

The historical data trend for LTR Pharma's Accumulated other comprehensive income (loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LTR Pharma Accumulated other comprehensive income (loss) Chart

LTR Pharma Annual Data
Trend Jun21 Jun22 Jun23
Accumulated other comprehensive income (loss)
- 0.05 0.58

LTR Pharma Semi-Annual Data
Jun21 Jun22 Jun23
Accumulated other comprehensive income (loss) - 0.05 0.58

LTR Pharma Accumulated other comprehensive income (loss) Calculation

Accumulated other comprehensive income (loss) is the aggregate amount of gains or losses that are not part of retained earnings.

LTR Pharma Accumulated other comprehensive income (loss) Related Terms

Thank you for viewing the detailed overview of LTR Pharma's Accumulated other comprehensive income (loss) provided by GuruFocus.com. Please click on the following links to see related term pages.

LTR Pharma (ASX:LTP) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » LTR Pharma Ltd (ASX:LTP) » Definitions » Accumulated other comprehensive income (loss)
Comparable Companies
Traded in Other Exchanges
N/A
Address
9A/204 Alice Street, Brisbane, QLD, AUS, 4000
Website
https://www.ltrpharma.com
LTR Pharma Ltd is a clinical stage pharmaceutical company focused on holistically improving men's health, physically and mentally, through the commercialization of an intranasal spray treatment for Erectile Dysfunction. SPONTAN is a Vardenafil-based nasal delivery formulation designed to be a lower dose fast-acting administration that provides a rapid and high availability to a patient's bloodstream compared with the incumbent oral ED treatment products on market.

LTR Pharma (ASX:LTP) Headlines

No Headlines